Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05239182
Title 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
Acronym RiLEY
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Kansas Medical Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Kansas University Cancer Center Fairway Kansas 66205 United States Details
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field